MX2013012259A - Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos. - Google Patents

Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.

Info

Publication number
MX2013012259A
MX2013012259A MX2013012259A MX2013012259A MX2013012259A MX 2013012259 A MX2013012259 A MX 2013012259A MX 2013012259 A MX2013012259 A MX 2013012259A MX 2013012259 A MX2013012259 A MX 2013012259A MX 2013012259 A MX2013012259 A MX 2013012259A
Authority
MX
Mexico
Prior art keywords
analogs
grf
growth hormone
releasing factor
hormone releasing
Prior art date
Application number
MX2013012259A
Other languages
English (en)
Spanish (es)
Inventor
Krishna G Peri
Abdelkrim Habi
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of MX2013012259A publication Critical patent/MX2013012259A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2013012259A 2011-04-21 2012-04-17 Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos. MX2013012259A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477775P 2011-04-21 2011-04-21
PCT/CA2012/050242 WO2012142706A1 (en) 2011-04-21 2012-04-17 Growth hormone releasing factor (grf) analogs and uses thereof

Publications (1)

Publication Number Publication Date
MX2013012259A true MX2013012259A (es) 2013-11-22

Family

ID=47021786

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012259A MX2013012259A (es) 2011-04-21 2012-04-17 Analogos del factor de liberacion de la hormona de crecimiento (grf) y usos de estos.

Country Status (10)

Country Link
US (1) US8361964B2 (enExample)
EP (1) EP2699591A4 (enExample)
JP (1) JP6113144B2 (enExample)
KR (1) KR20140027284A (enExample)
CN (1) CN103547591A (enExample)
AR (1) AR087727A1 (enExample)
BR (1) BR112013027150A2 (enExample)
CA (1) CA2833434A1 (enExample)
MX (1) MX2013012259A (enExample)
WO (1) WO2012142706A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
MX2018012716A (es) * 2016-04-19 2019-02-11 Griffon Pharmaceuticals Inc Peptidos bioactivos pegilados y usos de los mismos.
CA3183299A1 (en) * 2020-07-05 2022-01-13 Christian Marsolais Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4617149A (en) 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4622312A (en) 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4801456A (en) 1987-07-09 1989-01-31 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
EP0307860B1 (en) * 1987-09-18 1994-06-08 F. Hoffmann-La Roche Ag Cyclic GRF-analogs
IL97885A0 (en) * 1990-04-24 1992-06-21 Lilly Co Eli Growth hormone releasing factor analogs
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
US5262519A (en) * 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
DK0828758T3 (da) 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
US6057422A (en) 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
US7256258B2 (en) 2000-10-05 2007-08-14 Ares Trading S.A. Regioselective liquid phase pegylation
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
EP1539959A2 (en) 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
AU2003229222B2 (en) 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
WO2006042408A1 (en) 2004-10-20 2006-04-27 Theratechnologies Inc. Gh secretagogues and uses thereof
TW200517400A (en) 2003-08-05 2005-06-01 Univ Tulane Antagonistic analogs of GH-RH (2003)
US7893025B2 (en) 2003-10-20 2011-02-22 Theratechnolgies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
US20110021429A1 (en) 2007-10-01 2011-01-27 Pierrette Gaudreau Renoprotection by growth hormone-releasing hormone and agonists
EP2421548A4 (en) 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT

Also Published As

Publication number Publication date
CA2833434A1 (en) 2012-10-26
US20120270784A1 (en) 2012-10-25
CN103547591A (zh) 2014-01-29
WO2012142706A1 (en) 2012-10-26
EP2699591A1 (en) 2014-02-26
JP2014515751A (ja) 2014-07-03
BR112013027150A2 (pt) 2017-06-06
EP2699591A4 (en) 2014-05-07
US8361964B2 (en) 2013-01-29
JP6113144B2 (ja) 2017-04-12
KR20140027284A (ko) 2014-03-06
AR087727A1 (es) 2014-04-16

Similar Documents

Publication Publication Date Title
NZ612297A (en) Glucagon analogs exhibiting gip receptor activity
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
TN2012000567A1 (en) Glucagon analogues
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
NZ631445A (en) Anti-fgfr2 antibody
EP2718317A4 (en) GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
SG10201906304TA (en) Use of perfusion decellularized liver for islet cell recellularization
TN2012000560A1 (en) Glucagon analogues
PL3111926T3 (pl) Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
MX358161B (es) Analogos de hormona paratiroidea y usos para los mismos.
DOP2012000244A (es) Nuevos péptidos y métodos para su preparación y uso
PH12015502593A1 (en) COMPOSITIONS, METHODS and SYSTEMS FOR RESPIRATORY DELIVERY OF THREE OR MORE ACTIVE AGENTS
TW201144301A (en) Processes for preparing linezolid
IL221808B (en) Method for obtaining biologically active recombinant human g-csf
MX2012003951A (es) Preparacion farmceutica que comprende hcg recombinante.
WO2012015975A3 (en) Glp-1 receptor agonist compounds having stabilized regions
GB201201314D0 (en) Composition
ZA201403189B (en) Method for preparing physiologically active polypeptide complex
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
IL220648A0 (en) Stable growth hormone compounds
EP2682122A4 (en) GROWTH HORMONE SEKRETIONSPROMOTER
PT2916829T (pt) Utilização de material baseado em óxido de silício para a libertação modificada de agentes biologicamente ativos
MX2013011629A (es) Uso de un agente que consiste en anticuerpos y/o antagonistas de factor de crecimiento tipo insulina.

Legal Events

Date Code Title Description
FG Grant or registration